#1 Clinical Trials Search in Europe
EU – Europe
AT – Austria
HR – Croatia
CZ – Czech Republic
DK – Denmark
EE – Estonia
FI – Finland
FR – France
DE – Germany
IS – Iceland
IT – Italy
LV – Latvia
LT – Lithuania
NL – Netherlands
NO – Norway
PL – Poland
PT – Portugal
RO – Romania
SK – Slovakia
SI – Slovenia
ES – Spain
SE – Sweden
  • Find a Clinical Trial

    Search Trials by Disease

    Non-small cell lung cancer Breast cancer Plasma cell myeloma Neoplasm Neoplasm malignant Acute myeloid leukaemia Colitis ulcerative Obesity Colorectal cancer metastatic Prostate cancer Crohn's disease Colorectal cancer Ovarian cancer Dementia Alzheimer's type Hepatocellular carcinoma Breast cancer metastatic Dermatitis atopic Asthma Non-small cell lung cancer metastatic Malignant melanoma More trials…
  • Rare Diseases Treatments

    Search Trials by Disease

    Congenital leptin deficiency Stiff person syndrome Peritoneal mesothelioma malignant Acute lymphocytic leukaemia Interstitial lung disease Polycystic liver disease Epileptic encephalopathy Chronic inflammatory demyelinating polyradiculoneuropathy Breast angiosarcoma metastatic Infantile spasms Neonatal asphyxia Metastatic malignant melanoma Palmoplantar pustulosis Hypocalcaemia Phenylketonuria More trials…

    Learn about Rare Diseases

    Inclusion body myositis – Life with Disease Osteosarcoma metastatic – Treatment Cholangitis sclerosing VEXAS syndrome Familial amyotrophic lateral sclerosis – Life with Disease Immunodeficiency congenital – Treatment Anaplastic thyroid cancer – Diagnostics Basal cell naevus syndrome Retinoblastoma – Trials in Disease Angiosarcoma non-metastatic – Diagnostics More diseases
  • Vaccine Clinical Trials
  • Pediatric Clinical Trials
  • Resources for Patients

    Browse Innovative Treatments

    Amniotic Membrane, Human GAXILOSE Wt1 Lamp Mrna Dc Atomoxetine Hydrochloride Hydroxycarbamide Birtamimab Regn7075 Losartan Potassium Ofloxacin Hydrochloride Histamine Hydrochloride SAROGLITAZAR HEMIMAGNESIUM Ziftomenib Vx-522 Pristinamycin Gsk4011499 Ramucirumab Gremubamab Lib-01 Monohydrate Anidulafungin Odm-212 More therapies…

    Learn about Your Condition

    Anorexia nervosa Agitation Alport's syndrome Hepatitis B Meningioma Thrombocytosis Endometrial cancer stage II Neuropathy peripheral Diabetes insipidus Inflammatory bowel disease Supraventricular tachycardia Hepatic angiosarcoma Juvenile idiopathic arthritis Incontinence Hyperadrenocorticism More diseases
  • Healthy Volunteers
  • Patient Guide
  • Our Partners
  • About Us
  • Contact us
  • Region
    🇪🇺 Europe
    🇦🇹 Austria
    🇭🇷 Croatia
    🇨🇿 Czech Republic
    🇩🇰 Denmark
    🇪🇪 Estonia
    🇫🇮 Finland
    🇫🇷 France
    🇩🇪 Germany
    🇮🇸 Iceland
    🇮🇹 Italy
    🇱🇻 Latvia
    🇱🇹 Lithuania
    🇳🇱 Netherlands
    🇳🇴 Norway
    🇵🇱 Poland
    🇵🇹 Portugal
    🇷🇴 Romania
    🇸🇰 Slovakia
    🇸🇮 Slovenia
    🇪🇸 Spain
    🇸🇪 Sweden

Malignant mast cell neoplasm

  • Study of BNT326 alone and with BNT327 in patients with advanced solid tumors: Testing safety and effectiveness of new cancer treatments

    Recruiting

    1 1 1
    Investigated Drugs:
    • BNT327
    Belgium Germany Italy Spain

  • Phase 1/2 Study of VS-7375 with Drug Combination in Patients with Advanced KRAS G12D‑Mutated Solid Tumors

    Not yet recruiting

    1 1 1 1
    Investigated Drugs:
    • Carboplatin
    • Cetuximab
    • Gemcitabine
    Belgium France Germany Italy The Netherlands Spain

  • Study of BDC-1001 and Nivolumab for Patients with Advanced HER2-Positive Solid Tumors

    Not recruiting

    1 1 1 1
    Investigated Diseases:
    • HER2 protein overexpression
    • Malignant mast cell neoplasm
    Investigated Drugs:
    • Bdc-1001
    • Nivolumab
    France

  • Study on the Safety and Effects of Livmoniplimab and Budigalimab in Patients with Advanced or Metastatic Solid Tumors

    Not recruiting

    1 1 1
    Investigated Diseases:
    • Malignant mast cell neoplasm
    Investigated Drugs:
    • Budigalimab
    • Livmoniplimab
    Belgium France Germany Italy Poland Spain

  • Study on the Safety and Effects of BNT314 Alone or with Pembrolizumab for Patients with Advanced Solid Tumors

    Not recruiting

    1 1 1
    Investigated Diseases:
    • Malignant mast cell neoplasm
    Investigated Drugs:
    • Bnt314
    Belgium Denmark Spain

  • Study of Entrectinib in Children and Adolescents with Advanced or Metastatic Solid Tumors or Primary CNS Tumors with No Satisfactory Treatment Options

    Not recruiting

    1 1 1
    Investigated Diseases:
    • Malignant mast cell neoplasm
    Investigated Drugs:
    • Entrectinib
    France Germany Italy Spain
1 2
Next Page

Investigational Drugs in This Location

See which drug candidates are part of clinical trials near you. Click for detailed trial information.

Medical Conditions Being Studied in This Location

Explore diseases currently included in clinical trials near you. Click to view trials and details for each condition.

European Clinical Trials Information Network

The European Clinical Trials Information Network is transforming access to clinical trial information for patients across Europe. By overcoming language barriers, our platform allows everyone, regardless of their native language, to easily find relevant and comprehensible clinical trial data. This innovative service connects patients to cutting-edge treatments, creating a unified European community where health and progress transcend borders.

This service is not affiliated with the European Commission, the EMA, or the official CTIS system. Most information comes from publicly available international clinical-trial registries, supplemented by data from academic centres, national regulators, and commercial sponsors. We aim to keep all content accurate and up to date.

Explore the full ecosystem of clinical research in Europe.

The information provided on this website is mainly derived from international public clinical trial databases (CTIS.eu). In addition, we are including supplementary sources, such as information provided by academic centers and national regulators, as well as information supplied by commercial sponsors (pharmaceutical companies and contract research organizations). We try to ensure that the information provided is accurate and up to date.

Certain content and visual elements on this website have been generated or enhanced using artificial intelligence (AI).

The website is published by:
CTIN POLAND sp. z o.o.
with its registered office in Warsaw,
ul. rtm. Witolda Pileckiego 67/109,
02-781 Warsaw, Poland,
entered in the Register of Entrepreneurs of the National Court Register under KRS number 0001111334,
REGON: 528919042, NIP (Tax ID): 9512598637
Contact us

© 2026 CTIN Poland

Privacy Policy

Terms and Conditions

Contact

For Sites and Sponsors

Clinical Trial Locations

We use cookies

The website uses cookies to ensure the proper functioning of the site and to analyze internet traffic. Some cookies are essential for using the service and do not require consent. You can accept all cookies or use only the essential ones. Data is processed in accordance with our Privacy Policy. You have the right to withdraw your consent, access, rectify, delete, or limit the processing of your data at any time.
Numer nieprawidłowy!
Numer nieprawidłowy!